DPT Laboratories has announced today that Kuljit S Bhatia has been named vice-president of research and development.
Bhatia, who has more than 15 years of pharmaceutical experience in drug product development, previously was vice-president of research and development and technical operations at Fougera Pharmaceuticals (formerly Nycomed) in Long Island, NY.
At Fougera, he led pre-formulation and formulation development, analytical development and validation, process development, technical operations, package engineering and CMC project management.
Prior to joining Fougera, he held senior R&D positions at Medicis Pharmaceuticals and Mylan Technologies Inc.
"Dr. Bhatia brings extensive experience in comprehensive pharmaceutical development services, along with specific expertise in the area of topical pharmaceutical products, which applies directly to the semi-solid and liquid dosage forms that are our focus at DPT," said Paul Johnson, president of DPT.
"His broad understanding of the development process will be a critical asset in our efforts to enhance our continuum of services."
At DPT, Bhatia will provide leadership to the research and pharmaceutical development group and oversee DPT’s Center of Excellence for Research & Development in San Antonio.
Research and development activities at the center include pre-formulation and formulation development, analytical development and validation, process optimization, regulatory affairs support and transfer to DPT’s Center of Excellence for Semi-solids and Liquids, as well as to its Center of Excellence for Sterile and Specialty Products.
"I am excited to be a part of DPT, which has established a reputation as the leader in semisolid and liquid development," Bhatia said. "I believe my experience in pharmaceutical drug development will be a good strategic fit with the strong team of scientists DPT has in place, and I am looking forward to working with them to provide the best solutions to our customers’ needs."